MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling

Srijayaprakash Babu Uppada, Saiprasad Gowrikumar, Rizwan Ahmad, Balawant Kumar, Bryan Szeglin, Xi Chen, J. Joshua Smith, Surinder Kumar Batra, Amar Bahadur Singh, Punita Dhawan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Chemotherapeutic agents that modulate cell cycle checkpoints and/or tumor-specific pathways have shown immense promise in preclinical and clinical studies aimed at anti-cancer therapy. MASTL (Greatwall in Xenopus and Drosophila), a serine/threonine kinase controls the final G2/M checkpoint and prevents premature entry of cells into mitosis. Recent studies suggest that MASTL expression is highly upregulated in cancer and confers resistance against chemotherapy. However, the role and mechanism/s of MASTL mediated regulation of tumorigenesis remains poorly understood. Methods: We utilized a large patient cohort and mouse models of colon cancer as well as colon cancer cells to determine the role of Mastl and associated mechanism in colon cancer. Results: Here, we show that MASTL expression increases in colon cancer across all cancer stages compared with normal colon tissue (P < 0.001). Also, increased levels of MASTL associated with high-risk of the disease and poor prognosis. Further, the shRNA silencing of MASTL expression in colon cancer cells induced cell cycle arrest and apoptosis in vitro and inhibited xenograft-tumor growth in vivo. Mechanistic analysis revealed that MASTL expression facilitates colon cancer progression by promoting the β-catenin/Wnt signaling, the key signaling pathway implicated in colon carcinogenesis, and up-regulating anti-apoptotic proteins, Bcl-xL and Survivin. Further studies where colorectal cancer (CRC) cells were subjected to 5-fluorouracil (5FU) treatment revealed a sharp increase in MASTL expression upon chemotherapy, along with increases in Bcl-xL and Survivin expression. Most notably, inhibition of MASTL in these cells induced chemosensitivity to 5FU with downregulation of Survivin and Bcl-xL expression. Conclusion: Overall, our data shed light on the heretofore-undescribed mechanistic role of MASTL in key oncogenic signaling pathway/s to regulate colon cancer progression and chemo-resistance that would tremendously help to overcome drug resistance in colon cancer treatment.

Original languageEnglish (US)
Article number111
JournalMolecular Cancer
Volume17
Issue number1
DOIs
StatePublished - Aug 1 2018

Fingerprint

Catenins
Colonic Neoplasms
Neoplasms
Cell Cycle Checkpoints
Fluorouracil
Colon
Carcinogenesis
Drug Therapy
Apoptosis Regulatory Proteins
Protein-Serine-Threonine Kinases
Xenopus
Mitosis
Drug Resistance
Heterografts
Small Interfering RNA
Drosophila
Colorectal Neoplasms
Therapeutics
Down-Regulation
Apoptosis

Keywords

  • Colon cancer
  • Wnt signaling and MASTL

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling. / Uppada, Srijayaprakash Babu; Gowrikumar, Saiprasad; Ahmad, Rizwan; Kumar, Balawant; Szeglin, Bryan; Chen, Xi; Smith, J. Joshua; Batra, Surinder Kumar; Singh, Amar Bahadur; Dhawan, Punita.

In: Molecular Cancer, Vol. 17, No. 1, 111, 01.08.2018.

Research output: Contribution to journalArticle

Uppada, Srijayaprakash Babu ; Gowrikumar, Saiprasad ; Ahmad, Rizwan ; Kumar, Balawant ; Szeglin, Bryan ; Chen, Xi ; Smith, J. Joshua ; Batra, Surinder Kumar ; Singh, Amar Bahadur ; Dhawan, Punita. / MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling. In: Molecular Cancer. 2018 ; Vol. 17, No. 1.
@article{58f562870e354e74ae31d6d4540d2859,
title = "MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling",
abstract = "Background: Chemotherapeutic agents that modulate cell cycle checkpoints and/or tumor-specific pathways have shown immense promise in preclinical and clinical studies aimed at anti-cancer therapy. MASTL (Greatwall in Xenopus and Drosophila), a serine/threonine kinase controls the final G2/M checkpoint and prevents premature entry of cells into mitosis. Recent studies suggest that MASTL expression is highly upregulated in cancer and confers resistance against chemotherapy. However, the role and mechanism/s of MASTL mediated regulation of tumorigenesis remains poorly understood. Methods: We utilized a large patient cohort and mouse models of colon cancer as well as colon cancer cells to determine the role of Mastl and associated mechanism in colon cancer. Results: Here, we show that MASTL expression increases in colon cancer across all cancer stages compared with normal colon tissue (P < 0.001). Also, increased levels of MASTL associated with high-risk of the disease and poor prognosis. Further, the shRNA silencing of MASTL expression in colon cancer cells induced cell cycle arrest and apoptosis in vitro and inhibited xenograft-tumor growth in vivo. Mechanistic analysis revealed that MASTL expression facilitates colon cancer progression by promoting the β-catenin/Wnt signaling, the key signaling pathway implicated in colon carcinogenesis, and up-regulating anti-apoptotic proteins, Bcl-xL and Survivin. Further studies where colorectal cancer (CRC) cells were subjected to 5-fluorouracil (5FU) treatment revealed a sharp increase in MASTL expression upon chemotherapy, along with increases in Bcl-xL and Survivin expression. Most notably, inhibition of MASTL in these cells induced chemosensitivity to 5FU with downregulation of Survivin and Bcl-xL expression. Conclusion: Overall, our data shed light on the heretofore-undescribed mechanistic role of MASTL in key oncogenic signaling pathway/s to regulate colon cancer progression and chemo-resistance that would tremendously help to overcome drug resistance in colon cancer treatment.",
keywords = "Colon cancer, Wnt signaling and MASTL",
author = "Uppada, {Srijayaprakash Babu} and Saiprasad Gowrikumar and Rizwan Ahmad and Balawant Kumar and Bryan Szeglin and Xi Chen and Smith, {J. Joshua} and Batra, {Surinder Kumar} and Singh, {Amar Bahadur} and Punita Dhawan",
year = "2018",
month = "8",
day = "1",
doi = "10.1186/s12943-018-0848-3",
language = "English (US)",
volume = "17",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling

AU - Uppada, Srijayaprakash Babu

AU - Gowrikumar, Saiprasad

AU - Ahmad, Rizwan

AU - Kumar, Balawant

AU - Szeglin, Bryan

AU - Chen, Xi

AU - Smith, J. Joshua

AU - Batra, Surinder Kumar

AU - Singh, Amar Bahadur

AU - Dhawan, Punita

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Chemotherapeutic agents that modulate cell cycle checkpoints and/or tumor-specific pathways have shown immense promise in preclinical and clinical studies aimed at anti-cancer therapy. MASTL (Greatwall in Xenopus and Drosophila), a serine/threonine kinase controls the final G2/M checkpoint and prevents premature entry of cells into mitosis. Recent studies suggest that MASTL expression is highly upregulated in cancer and confers resistance against chemotherapy. However, the role and mechanism/s of MASTL mediated regulation of tumorigenesis remains poorly understood. Methods: We utilized a large patient cohort and mouse models of colon cancer as well as colon cancer cells to determine the role of Mastl and associated mechanism in colon cancer. Results: Here, we show that MASTL expression increases in colon cancer across all cancer stages compared with normal colon tissue (P < 0.001). Also, increased levels of MASTL associated with high-risk of the disease and poor prognosis. Further, the shRNA silencing of MASTL expression in colon cancer cells induced cell cycle arrest and apoptosis in vitro and inhibited xenograft-tumor growth in vivo. Mechanistic analysis revealed that MASTL expression facilitates colon cancer progression by promoting the β-catenin/Wnt signaling, the key signaling pathway implicated in colon carcinogenesis, and up-regulating anti-apoptotic proteins, Bcl-xL and Survivin. Further studies where colorectal cancer (CRC) cells were subjected to 5-fluorouracil (5FU) treatment revealed a sharp increase in MASTL expression upon chemotherapy, along with increases in Bcl-xL and Survivin expression. Most notably, inhibition of MASTL in these cells induced chemosensitivity to 5FU with downregulation of Survivin and Bcl-xL expression. Conclusion: Overall, our data shed light on the heretofore-undescribed mechanistic role of MASTL in key oncogenic signaling pathway/s to regulate colon cancer progression and chemo-resistance that would tremendously help to overcome drug resistance in colon cancer treatment.

AB - Background: Chemotherapeutic agents that modulate cell cycle checkpoints and/or tumor-specific pathways have shown immense promise in preclinical and clinical studies aimed at anti-cancer therapy. MASTL (Greatwall in Xenopus and Drosophila), a serine/threonine kinase controls the final G2/M checkpoint and prevents premature entry of cells into mitosis. Recent studies suggest that MASTL expression is highly upregulated in cancer and confers resistance against chemotherapy. However, the role and mechanism/s of MASTL mediated regulation of tumorigenesis remains poorly understood. Methods: We utilized a large patient cohort and mouse models of colon cancer as well as colon cancer cells to determine the role of Mastl and associated mechanism in colon cancer. Results: Here, we show that MASTL expression increases in colon cancer across all cancer stages compared with normal colon tissue (P < 0.001). Also, increased levels of MASTL associated with high-risk of the disease and poor prognosis. Further, the shRNA silencing of MASTL expression in colon cancer cells induced cell cycle arrest and apoptosis in vitro and inhibited xenograft-tumor growth in vivo. Mechanistic analysis revealed that MASTL expression facilitates colon cancer progression by promoting the β-catenin/Wnt signaling, the key signaling pathway implicated in colon carcinogenesis, and up-regulating anti-apoptotic proteins, Bcl-xL and Survivin. Further studies where colorectal cancer (CRC) cells were subjected to 5-fluorouracil (5FU) treatment revealed a sharp increase in MASTL expression upon chemotherapy, along with increases in Bcl-xL and Survivin expression. Most notably, inhibition of MASTL in these cells induced chemosensitivity to 5FU with downregulation of Survivin and Bcl-xL expression. Conclusion: Overall, our data shed light on the heretofore-undescribed mechanistic role of MASTL in key oncogenic signaling pathway/s to regulate colon cancer progression and chemo-resistance that would tremendously help to overcome drug resistance in colon cancer treatment.

KW - Colon cancer

KW - Wnt signaling and MASTL

UR - http://www.scopus.com/inward/record.url?scp=85051022188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051022188&partnerID=8YFLogxK

U2 - 10.1186/s12943-018-0848-3

DO - 10.1186/s12943-018-0848-3

M3 - Article

VL - 17

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 111

ER -